source
- SK Biopharma signs $795 million licensing deal with Biohaven for epilepsy therapy opakalimSK Biopharma has entered a licensing agreement with Biohaven Pharmaceuticals to acquire worldwide rights to the Kv7 ion channel activator opakalim (BHV-7000) for epilepsy. The deal provides an upf…
- Inhalable modified tRNA restores lung protein function in cystic fibrosis mice, shows promise for genetic diseasesUniversity of Toronto scientists have shown that an inhalable form of modified transfer RNA can safely reach the lungs of mice carrying a nonsense mutation that causes cystic fibrosis. The treatmen…Fierce Biotech · 3d agoPositive readoutPositive